Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities
Riociguat is licensed for the therapy of inoperable chronic thromboembolic pulmonary hypertension (CTEPH). We aimed to investigate whether age and comorbidities influence its tolerability and efficacy. Retrospectively, we analyzed data of tolerability, non-invasive, and invasive efficacy at baseline...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/4/1084 |
| _version_ | 1797479129351716864 |
|---|---|
| author | Michaela Barnikel Nikolaus Kneidinger Paola Arnold Andrea Waelde Jürgen Behr Katrin Milger |
| author_facet | Michaela Barnikel Nikolaus Kneidinger Paola Arnold Andrea Waelde Jürgen Behr Katrin Milger |
| author_sort | Michaela Barnikel |
| collection | DOAJ |
| description | Riociguat is licensed for the therapy of inoperable chronic thromboembolic pulmonary hypertension (CTEPH). We aimed to investigate whether age and comorbidities influence its tolerability and efficacy. Retrospectively, we analyzed data of tolerability, non-invasive, and invasive efficacy at baseline and follow up (FU) of all patients with CTEPH treated with riociguat at the Department of Internal Medicine V, University of Munich (<i>n</i> = 47), grouping patients according to age (<65 versus 65–79 versus ≥80 years) and risk factors for heart failure with preserved ejection fraction (HFpEF) (<2 versus ≥2 risk factors). During dose titration patients >80 years reported side effects more frequently (40%) than the other age groups (23% and 21% for patients <65 years and patients 65–79, respectively). Cessation of riociguat was rare and occurred independent of age. When looking at the total cohort of 47 patients, three patients stopped therapy and three patients had a reduced maintenance dosage, while 41/47 (87%) and all octogenarians reached the highest maintenance dosage of 7.5 mg/d. The frequency of any side effect was similar in patients in both risk factor groups, and hypotension was only observed in those with <2 risk factors. Parameters of efficacy improved significantly under riociguat treatment. Improvement in 6-min walk distance (6 mwd), N-terminal pro brain natriuretic peptide (Nt-proBNP) and hemodynamics did not differ between age or risk factor groups. In this small real-life cohort, riociguat was well-tolerated and effective in advanced age and risk factors for HFpEF. |
| first_indexed | 2024-03-09T21:41:12Z |
| format | Article |
| id | doaj.art-9fefbec5201f49daa976534cc2b0f745 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T21:41:12Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-9fefbec5201f49daa976534cc2b0f7452023-11-23T20:31:24ZengMDPI AGJournal of Clinical Medicine2077-03832022-02-01114108410.3390/jcm11041084Riociguat in Patients with CTEPH and Advanced Age and/or ComorbiditiesMichaela Barnikel0Nikolaus Kneidinger1Paola Arnold2Andrea Waelde3Jürgen Behr4Katrin Milger5Department of Internal Medicine V, Ludwig Maximilian University of Munich, 81377 Munich, GermanyDepartment of Internal Medicine V, Ludwig Maximilian University of Munich, 81377 Munich, GermanyDepartment of Internal Medicine V, Ludwig Maximilian University of Munich, 81377 Munich, GermanyDepartment of Internal Medicine V, Ludwig Maximilian University of Munich, 81377 Munich, GermanyDepartment of Internal Medicine V, Ludwig Maximilian University of Munich, 81377 Munich, GermanyDepartment of Internal Medicine V, Ludwig Maximilian University of Munich, 81377 Munich, GermanyRiociguat is licensed for the therapy of inoperable chronic thromboembolic pulmonary hypertension (CTEPH). We aimed to investigate whether age and comorbidities influence its tolerability and efficacy. Retrospectively, we analyzed data of tolerability, non-invasive, and invasive efficacy at baseline and follow up (FU) of all patients with CTEPH treated with riociguat at the Department of Internal Medicine V, University of Munich (<i>n</i> = 47), grouping patients according to age (<65 versus 65–79 versus ≥80 years) and risk factors for heart failure with preserved ejection fraction (HFpEF) (<2 versus ≥2 risk factors). During dose titration patients >80 years reported side effects more frequently (40%) than the other age groups (23% and 21% for patients <65 years and patients 65–79, respectively). Cessation of riociguat was rare and occurred independent of age. When looking at the total cohort of 47 patients, three patients stopped therapy and three patients had a reduced maintenance dosage, while 41/47 (87%) and all octogenarians reached the highest maintenance dosage of 7.5 mg/d. The frequency of any side effect was similar in patients in both risk factor groups, and hypotension was only observed in those with <2 risk factors. Parameters of efficacy improved significantly under riociguat treatment. Improvement in 6-min walk distance (6 mwd), N-terminal pro brain natriuretic peptide (Nt-proBNP) and hemodynamics did not differ between age or risk factor groups. In this small real-life cohort, riociguat was well-tolerated and effective in advanced age and risk factors for HFpEF.https://www.mdpi.com/2077-0383/11/4/1084hemodynamicsefficacytolerability |
| spellingShingle | Michaela Barnikel Nikolaus Kneidinger Paola Arnold Andrea Waelde Jürgen Behr Katrin Milger Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities Journal of Clinical Medicine hemodynamics efficacy tolerability |
| title | Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities |
| title_full | Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities |
| title_fullStr | Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities |
| title_full_unstemmed | Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities |
| title_short | Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities |
| title_sort | riociguat in patients with cteph and advanced age and or comorbidities |
| topic | hemodynamics efficacy tolerability |
| url | https://www.mdpi.com/2077-0383/11/4/1084 |
| work_keys_str_mv | AT michaelabarnikel riociguatinpatientswithctephandadvancedageandorcomorbidities AT nikolauskneidinger riociguatinpatientswithctephandadvancedageandorcomorbidities AT paolaarnold riociguatinpatientswithctephandadvancedageandorcomorbidities AT andreawaelde riociguatinpatientswithctephandadvancedageandorcomorbidities AT jurgenbehr riociguatinpatientswithctephandadvancedageandorcomorbidities AT katrinmilger riociguatinpatientswithctephandadvancedageandorcomorbidities |